Phase II Trial of Nab-Paclitaxel as First Line cytotoxic Chemotherapy in Patients with Unresectable Cutaneous Squamous Cell Carcinoma

ID Number 12-1697

Principal Investigator(s)
Philip Friedlander

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to determine if the chemotherapy called nab-paclitaxel (abraxane) can shrink or slow the growth of squamous cell carcinoma (SCC) which developed on the skin surface and has spread throughout the body. Chemotherapy is often used to treat SCC that has spread throughout the body but the effectiveness of different types of chemotherapy has not been researched in great detail. Oncologists often choose the chemotherapy without good supporting data from clinical trials to show that the chemotherapy works well. Currently there are no FDA approved chemotherapies for metastatic cutaneous SCC.

Contact Information
(212) 824-7309

Recruiting Patients: Yes